EQUITY PURCHASE AGREEMENT BY AND BETWEEN MUSCLEPHARM CORPORATION AND SOUTHRIDGE PARTNERS II, LP Dated November 4, 2011Equity Purchase Agreement • December 29th, 2011 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledDecember 29th, 2011 Company Industry JurisdictionTHIS EQUITY PURCHASE AGREEMENT entered into as of the 4th day of November, 2011 (this “AGREEMENT”), by and between SOUTHRIDGE PARTNERS II, LP, Delaware limited partnership (“INVESTOR”), and MUSCLEPHARM CORPORATION, a Nevada corporation (the “COMPANY”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 28th, 2013 • MusclePharm Corp • Pharmaceutical preparations
Contract Type FiledMarch 28th, 2013 Company IndustryTHIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of ___, 2013, among MusclePharm Corporation, a Nevada corporation (the “Company”), and each signatory hereto (each, an “Investor” and collectively, the “Investors”).
PLACEMENT AGENCY AGREEMENT January 16, 2013Placement Agency Agreement • January 23rd, 2013 • MusclePharm Corp • Pharmaceutical preparations • Colorado
Contract Type FiledJanuary 23rd, 2013 Company Industry Jurisdiction
SECURITY AGREEMENTSecurity Agreement • July 20th, 2012 • MusclePharm Corp • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 20th, 2012 Company Industry JurisdictionTHIS SECURITY AGREEMENT (“Agreement”) is made as of this _____________, by and between MUSCLEPHARM CORPORATION, a Nevada corporation (the “Company”), in favor of TCA GLOBAL CREDIT MASTER FUND, LP, a Cayman Islands limited partnership (the “Secured Party”).
ContractWarrant Agreement • November 14th, 2011 • MusclePharm Corp • Pharmaceutical preparations • Utah
Contract Type FiledNovember 14th, 2011 Company Industry JurisdictionTHIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SUCH ACT AND ANY APPLICABLE STATE SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO MUSCLEPHARM CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.
SUBSCRIPTION AGREEMENTSubscription Agreement • March 28th, 2013 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledMarch 28th, 2013 Company Industry JurisdictionTHIS SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of the last date set forth on the signature page hereof between MusclePharm Corporation, a Nevada corporation (the “Company”), and the undersigned (the “Subscriber”). The Company is conducting a private placement (the “Offering”) of shares (the “Shares” or the “Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $8.50 per Share.
COMMITTED EQUITY FACILITY AGREEMENTCommitted Equity Facility Agreement • July 20th, 2012 • MusclePharm Corp • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 20th, 2012 Company Industry JurisdictionThis Committed Equity Facility Agreement (the “Agreement”) is dated as of the __________________, by and between TCA GLOBAL CREDIT MASTER FUND, LP, a Cayman Islands limited partnership (the “Investor”) and MUSCLEPHARM CORPORATION, a Nevada corporation (the “Company”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • April 16th, 2012 • MusclePharm Corp • Pharmaceutical preparations
Contract Type FiledApril 16th, 2012 Company IndustryThis AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made as of November 14, 2011, by and between MusclePharm Corporation, a Nevada corporation with offices at 4721 Ironton Street, Building A, Denver, CO 90839 (hereinafter called the “Company”), and Brad J. Pyatt, residing at 4721 Ironton Street, Building A, Denver, CO 80239 (hereinafter referred to as the “Executive”). This Agreement amends, restates and replaces in its entirety, the Original Agreement (as defined below).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 2nd, 2018 • MusclePharm Corp • Pharmaceutical preparations • Colorado
Contract Type FiledApril 2nd, 2018 Company Industry JurisdictionTHIS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered as of March __, 2018 and effective as of January 1, 2018 (the "Effective Date"), by and between MusclePharm Corporation, a Nevada Corporation (the "Company"), and Brian Casutto, an individual ("Executive"). The Company and Executive are sometimes referred to herein as a "party" or collectively as the "parties."
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 30th, 2013 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledAugust 30th, 2013 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”)is dated as of August 26, 2013, between Biozone Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the purchasers signatory hereto (the each a “Purchaser” and collectively, the “Purchasers”).
COMMON STOCK PURCHASE WARRANT MUSCLEPHARM CORPORATIONSecurity Agreement • June 9th, 2022 • MusclePharm Corp • Pharmaceutical preparations
Contract Type FiledJune 9th, 2022 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June [ ], 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from MusclePharm Corporation, a Nevada corporation (the “Company”), up to [ ] shares1 (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
NOTE AND WARRANT PURCHASE AGREEMENTNote and Warrant Purchase Agreement • November 14th, 2011 • MusclePharm Corp • Pharmaceutical preparations • Utah
Contract Type FiledNovember 14th, 2011 Company Industry JurisdictionTHIS NOTE AND WARRANT PURCHASE AGREEMENT, dated as of June 29, 2011 (this “Agreement”), is entered into by and between MUSCLEPHARM CORPORATION, a Nevada corporation (the “Company”), and INTER-MOUNTAIN CAPITAL CORP., a Delaware corporation, its successors or assigns (the “Buyer”).
Sixth Amended and Restated Security AgreementSecurity Agreement • December 3rd, 2020 • MusclePharm Corp • Pharmaceutical preparations • California
Contract Type FiledDecember 3rd, 2020 Company Industry JurisdictionThis Sixth Amended and Restated Security Agreement (this “Agreement”), dated as of November 29, 2020, is entered into between Ryan Drexler, an individual (“Grantee”), and MusclePharm Corporation, a Nevada corporation, as grantor (“Grantor”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 19th, 2012 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledJuly 19th, 2012 Company Industry JurisdictionTHIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), is dated as of July 10, 2012, by and between MUSCLEPHARM CORPORATION., a Nevada corporation (the “Company”), and the subscribers set forth on the signature pages affixed hereto (each a “Subscriber” and collectively, the “Subscribers”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 14th, 2011 • MusclePharm Corp • Pharmaceutical preparations • Colorado
Contract Type FiledNovember 14th, 2011 Company Industry JurisdictionThis EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of this 15th day of September, 2011 (the “Effective Date”), by and between MUSCLE PHARM CORP., a Nevada corporation (the “Company”), and, John H. Bluher, an individual (the “Executive”). Company or Executive are sometimes referred to herein as “party” or collectively “parties”.
SUBSCRIPTION AGREEMENTSubscription Agreement • January 28th, 2013 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledJanuary 28th, 2013 Company Industry JurisdictionThis Subscription Agreement (this “Agreement”) is dated as of ____________, 2013, between MusclePharm Corporation, a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • September 8th, 2017 • MusclePharm Corp • Pharmaceutical preparations • Nevada
Contract Type FiledSeptember 8th, 2017 Company Industry JurisdictionThis Indemnification Agreement (this “Agreement”) is made as of ______________ ___, _____, by and between MusclePharm Corporation, a Nevada corporation (the “Company”), and ______________________ (“Indemnitee”).
RESTRICTED STOCK AGREEMENT (Non-Assignable) [17% of grant] Shares of Restricted Stock of MusclePharm CorporationRestricted Stock Agreement • July 5th, 2013 • MusclePharm Corp • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 5th, 2013 Company Industry JurisdictionTHIS CERTIFIES that on July __, 2013, [NAME] (“Holder”) was granted [17% OF SHARE GRANTED] ([insert # = to 17% of shares granted]) shares of fully paid and non-assessable shares (“Shares”) of the Restricted Stock (par value $0.001 per share) of MusclePharm Corporation (the “Corporation”), a Nevada corporation. A determination of the Compensation Committee of the Board of Directors of the Company (the “Committee”) as to any questions which may arise with respect to the interpretation of the provisions of this award shall be final.
FORM OF ESCROW AGREEMENTEscrow Agreement • December 26th, 2012 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledDecember 26th, 2012 Company Industry JurisdictionThis ESCROW AGREEMENT (this “Agreement”) dated as of December 20, 2012, among MusclePharm Corporation, a Nevada corporation (the “Issuer”), and Aegis Capital Corp. (the “Placement Agent”), whose addresses and other information appear on the Information Sheet (as defined herein) attached to this Agreement, and Continental Stock Transfer & Trust Company, 17 Battery Place, 8th Floor, New York, NY 10004 (the “Escrow Agent”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 16th, 2016 • MusclePharm Corp • Pharmaceutical preparations • Colorado
Contract Type FiledFebruary 16th, 2016 Company Industry JurisdictionThis EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 11th day of February 2016, by and between MusclePharm Corporation, a Nevada corporation headquartered at 4721 Ironton Street, Building A, Denver, Colorado 80239 (“Company”) and Ryan Drexler (“Executive”). As used herein, the “Effective Date” of this Agreement shall mean February 10, 2016.
SEPARATION AGREEMENTSeparation Agreement • August 10th, 2015 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledAugust 10th, 2015 Company Industry JurisdictionThis Separation Agreement (the “Agreement”) is made as of the 19th day of May, 2015 (the “Effective Date”), by and between MusclePharm Corporation (“MusclePharm” or the “Company”), a Nevada corporation, and Mr. Andrew J. Lupo (“Resigning Director”) (Company and Resigning Director hereinafter referred to from time to time together as the “Parties”).
ENDORSEMENT LICENSING AND CO-BRANDING AGREEMENTEndorsement Licensing and Co-Branding Agreement • March 31st, 2014 • MusclePharm Corp • Pharmaceutical preparations • California
Contract Type FiledMarch 31st, 2014 Company Industry JurisdictionThis ENDORSEMENT LICENSING AND CO-BRANDING AGREEMENT is entered into on July 26, 2013 (the Effective Date”) by and between Marine MP, LLC (“Lender”), for services of Arnold Schwarzenegger (“Endorser”), and Fitness Publications, Inc. (“Fitness”) (collectively, Lender, Endorser, and Fitness are referred to as the “AS Parties”) and MusclePharm Corporation with its principal place of business in Denver, Colorado and its subsidiaries, (collectively, “MusclePharm” or the “Company”).
ESCROW DEPOSIT AGREEMENTEscrow Deposit Agreement • January 8th, 2013 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledJanuary 8th, 2013 Company Industry JurisdictionThis ESCROW DEPOSIT AGREEMENT (this “Agreement”) dated as of this __ day of _____2013, by and among MusclePharm Corporation, a Nevada corporation (the “Company”), having an address at 4721 Ironton Street, Building A, Denver, CO 80239, GVC Capital LLC (the “Placement Agent”), having an address at 5350 S. Roslyn St., Suite 400, Greenwood Village, Colorado 80111 and SIGNATURE BANK (the “Escrow Agent”), a New York State chartered bank, having an office at 950 Third avenue, 9th Floor, New York, NY 10022. All capitalized terms not herein defined shall have the meaning ascribed to them in that certain Post-Effective Amendment No. 1 to Form S-1, as filed with the Securities and Exchange Commission on January __, 2013 and as amended or supplemented from time-to-time, including all attachments, schedules and exhibits thereto.
ASSET PURCHASE AGREEMENT by and among MUSCLEPHARM CORPORATION, BIOZONE LABORATORIES INC., and BIOZONE PHARMACEUTICALS, INC., BIOZONE LABORATORIES, INC., BAKER CUMMINS CORP. and Brian Keller DATED November 12, 2013 ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 13th, 2013 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledNovember 13th, 2013 Company Industry JurisdictionMSLP, the Purchaser and the Sellers are at times collectively referred to herein individually as a “Party” and collectively as the “Parties.”
ContractSecurity Agreement • June 9th, 2022 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledJune 9th, 2022 Company Industry JurisdictionTHIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.
ContractPromissory Note • March 8th, 2012 • MusclePharm Corp • Pharmaceutical preparations • Colorado
Contract Type FiledMarch 8th, 2012 Company Industry JurisdictionTHIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "ACT") AND IS A "RESTRICTED SECURITY" AS THAT TERM IS DEFINED IN RULE 144 UNDER THE ACT. THE NOTE MAY NOT BE OFFERED FOR SALE, SOLD OR TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT, THE AVAILABILITY OF WHICH IS TO BE ESTABLISHED TO THE SATISFACTION OF THE COMPANY.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 10th, 2015 • MusclePharm Corp • Pharmaceutical preparations • Colorado
Contract Type FiledAugust 10th, 2015 Company Industry JurisdictionThis EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 24th day of June 2015, by and between MusclePharm Corporation, a Nevada corporation headquartered at 4721 Ironton Street, Building A, Denver, Colorado 80239 (“Company”) and Brad Pyatt, an individual residing at 11345 W. 38th AVE. Wheatridge, Co 80033 (“Executive”). As used herein, the “Effective Date” of this Agreement shall mean January 1, 2015.
FIRST AMENDMENT TO THE CONSULTING AGREEMENTConsulting Agreement • April 5th, 2013 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledApril 5th, 2013 Company Industry JurisdictionThis First Amendment to the Consulting Agreement (this “Amendment”) is made and effective as of March 28, 2013, by and between MusclePharm Corporation, a Nevada corporation (the “Company”), and GRQ Consultants, Inc. (the “Consultant”).
ContractNote Agreement • August 27th, 2020 • MusclePharm Corp • Pharmaceutical preparations • California
Contract Type FiledAugust 27th, 2020 Company Industry JurisdictionTHIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.
Separation and Release of Claims AgreementSeparation and Release of Claims Agreement • October 21st, 2014 • MusclePharm Corp • Pharmaceutical preparations • Colorado
Contract Type FiledOctober 21st, 2014 Company Industry JurisdictionThis Separation and Release of Claims Agreement (this “Agreement”) is dated as of October 10, 2014 (the “Execution Date”), by and between MusclePharm Corporation, a Nevada corporation (the “Company”), on behalf of itself, its subsidiaries and other corporate affiliates and each of their respective employees, officers, directors, owners, shareholders and agents (collectively referred to herein as, the “Employer Group”), and Sydney Rollock (the “Employee”). The Company and the Employee are sometimes collectively referred to herein as the “Parties.”
ContractNote Agreement • October 21st, 2020 • MusclePharm Corp • Pharmaceutical preparations • California
Contract Type FiledOctober 21st, 2020 Company Industry JurisdictionTHIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.
CONSULTING AGREEMENTConsulting Agreement • July 19th, 2012 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledJuly 19th, 2012 Company Industry JurisdictionThis Consulting Agreement (this "Agreement") is made and effective as of the 12th day of July, 2012, by and between MusclePharm Corporation, a Nevada corporation (the "Company"), and Melechdavid, Inc. ("Consultant").
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 14th, 2017 • MusclePharm Corp • Pharmaceutical preparations • Colorado
Contract Type FiledAugust 14th, 2017 Company Industry JurisdictionThis AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the ___ day of November 2016 (the “Amendment Date”), by and between MusclePharm Corporation, a Nevada corporation headquartered at 4721 Ironton Street, Building A, Denver, Colorado 80239 (“Company”) and Ryan Drexler (“Executive”). As used herein, the “Effective Date” of this Agreement shall mean February 10, 2016, the effective date of the previous employment agreement by and between the Executive and the Company (the “Prior Agreement”).
FIRST AMENDMENT TO MANUFACTURING AGREEMENTManufacturing Agreement • May 11th, 2015 • MusclePharm Corp • Pharmaceutical preparations
Contract Type FiledMay 11th, 2015 Company IndustryThis First Amendment (this “Amendment”), effective this second day of March 2015 (“Amendment Effective Date”), is made to the Manufacturing Agreement (“the Agreement”) originally effective November 27, 2013 and is entered into by and between F.H.G. Corporation a Florida corporation having a principle place of business in Spring Hill, Tennessee, formerly doing business as “Integrity” but now doing business as “Capstone Nutrition” (“Capstone Nutrition”) and MusclePharm Corporation (“MUSCLEPHARM”), a Nevada corporation having a principle place of business in Denver, Colorado.
RESTRUCTURING AGREEMENTRestructuring Agreement • November 8th, 2017 • MusclePharm Corp • Pharmaceutical preparations • New York
Contract Type FiledNovember 8th, 2017 Company Industry JurisdictionThis Restructuring Agreement (the “Agreement”) is made as of November 3, 2017, by and between Ryan Drexler, an individual (“Drexler”) and MusclePharm Corporation, a Nevada corporation (the “Company”).